Design, Synthesis, and Biological Evaluation of 4-Arylamino Pyrimidine Derivatives as FAK Inhibitors and Tumor Radiotracers.
Antineoplastic Agents
/ chemistry
Cell Line, Tumor
Cell Proliferation
Drug Design
Drug Screening Assays, Antitumor
Focal Adhesion Protein-Tyrosine Kinases
/ metabolism
Humans
Molecular Docking Simulation
Neoplasms
/ diagnostic imaging
Protein Kinase Inhibitors
/ chemistry
Structure-Activity Relationship
18F labeled
FAK inhibitor
focal adhesion kinase (FAK)
molecular docking
tumor radiotracers
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
04 07 2022
04 07 2022
Historique:
pubmed:
29
4
2022
medline:
8
7
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
Focal adhesion kinase (FAK) is considered a promising target for the diagnosis and treatment of cancer. In this work, a series of
Identifiants
pubmed: 35481371
doi: 10.1021/acs.molpharmaceut.2c00180
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Focal Adhesion Protein-Tyrosine Kinases
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM